Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study

Jing Sun, Aimin Zhang, Wengang Li, Quan Wang, Dong Li, Dan Zhang, Xuezhang Duan, Jing Sun, Aimin Zhang, Wengang Li, Quan Wang, Dong Li, Dan Zhang, Xuezhang Duan

Abstract

Background: There is a lack of data on the biologically effective dose and the efficacy of stereotactic body radiotherapy in hepatocellular carcinoma patients, and this study was conducted to explore the relation between BED and efficacy.

Methods: This study is designed as a mono-center study. The participants are randomized into three group, and received the following recommended schedule: 49Gy/7f, 54Gy/6f and 55Gy/5f with BED10 in correspondence to 83.3Gy, 102.6Gy and 115.5Gy. The primary outcome measures are to calculate local control rates (LC), overall survival rates (OS) and progression-free survival rates (PFS). The secondary outcome measures are to observe radiation-induced liver injury (RILD) rates, Child-Pugh score and indocyanine green retention rate at 15 min (ICG-R15) value before and after CK-SBRT. Moreover, gastrointestinal toxicities are also observed.

Discussion: There is no uniform standard for CK-SBRT dose schedule of hepatocellular carcinoma. We propose to conduct a study determining the optimal CK-SBRT schedule of hepatocellular carcinoma patients (≤5 cm). The trial protocol has been approved by the Institutional Review Board of 302 Hospital of PLA (People's Liberation Army). The Ethics number is 2017111D.

Trail registration: Clinical trails number: NCT03295500. Date of registration: November, 2017.

Keywords: Biologically effective dose; CyberKnife; Hepatocellular carcinoma; Protocol; Stereotactic body radiotherapy.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Zhang T, Sun J, He W, Li H, Piao J, Xu H, Duan X. Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma. BMC Cancer. 2018;18(1):451. doi: 10.1186/s12885-018-4359-9.
    1. Beskow C, Ågrencronqvist AK, Lewensohn R, Tomadasu I: Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery. J Contemp Brachytherapy 2012;4(4):205–12.
    1. Zhu Lucheng, Zhang Shirong, Xu Xiao, Wang Bing, Wu Kan, Deng Qinghua, Xia Bing, Ma Shenglin. Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review. PLOS ONE. 2016;11(5):e0156494. doi: 10.1371/journal.pone.0156494.
    1. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiation Oncol Biol Phys. 1995;31(5):1237. doi: 10.1016/0360-3016(94)00418-K.
    1. Liang SX, Huang XB, Zhu XD, Zhang WD, Cai L, Huang HZ, Li YF, Chen L, Liu MZ. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with child–Pugh grade a cirrhosis. Radiother Oncol. 2011;98(2):265–269. doi: 10.1016/j.radonc.2010.10.014.
    1. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3):S94–S100. doi: 10.1016/j.ijrobp.2009.06.092.
    1. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC) Int J Radiat Oncol Biol Phys. 2015;31(5):1341–1346. doi: 10.1016/0360-3016(95)00060-C.
    1. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–4101. doi: 10.1118/1.3438081.
    1. S J, Z T, W J, L W, Z A, H W, Z D, L D, D J, D X. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm) BMC Cancer. 2019;19(1):846. doi: 10.1186/s12885-019-6063-9.
    1. Youjin L, Auh SL, Yugang W, Byron B, Yang W, Yuru M, Michael B, Rohit S, Robert C, Tony T. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589. doi: 10.1182/blood-2009-02-206870.
    1. Schaue D, Ratikan JA, Iwamoto KS, Mcbride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–1310. doi: 10.1016/j.ijrobp.2011.09.049.
    1. Yoon Hong In, Koom Woong Sub, Lee Ik Jae, Jeong Kyoungkeun, Chung Yoonsun, Kim Ja Kyung, Lee Kwan Sik, Han Kwang-Hyub, Seong Jinsil. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver International. 2012;32(7):1165–1171. doi: 10.1111/j.1478-3231.2012.02784.x.
    1. Jun Baek Gyu, Kim Young Don, Cheon Gab Jin, Kim Eun Seog, Jwa Eunjin, Kim Sang Gyune, Kim Young Seok, Kim Boo Sung, Jeong Soung Won, Jang Jae Young, Lee Sae Hwan, Kim Hong Soo. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. The Korean Journal of Internal Medicine. 2018;33(6):1093–1102. doi: 10.3904/kjim.2016.412.
    1. C TR, B SR, S SK, Y RH, K SW, P JO, Y L, H WP, J GE, L IW, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8(3):157–166. doi: 10.1016/j.prro.2017.10.013.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever